Gliomas

[:nl]

Gliomen ontwikkelen zich van de ondersteunende cellen van de hersenen, de zogenaamde gliacellen.
Gliomen worden geclassificeerd door de World Health Organization in 4 klassen (WHO graad I tot en met IV). De meest agressieve vorm (WHO graad IV) wordt glioblastoma multiforme genoemd.
We maken bij de operaties gebruik van alle moderne technologie, waaronder neuronavigatie, neuromonitoring en wakkere chirurgie.
Het tumorweefsel wordt microscopisch onderzocht, waarbij wij moleculaire markers (MGMT, IDH, 1p19q etc.) in het tumorweefsel bepalen ter bevestiging van de diagnose.
Aangezien er nog steeds geen definitieve genezing voor de meeste gliomen bestaat, beschouwen we het als onze verantwoordelijkheid om als universitair ziekenhuis te werken aan een continue verbetering van de therapie, de prognose en de levenskwaliteit van patiënten met een glioom. We voeren daarom studies uit bij patiënten met gliomen binnen het ziekenhuis en nemen eveneens deel aan multicentrische nationale en internationale studies.

[:en]

Gliomas develop from the supporting cells of the brain, so-called glial cells.

Gliomas are classified by the World Health Organization in terms of their tissue structure and growth behavior into 4 grades (WHO grade I to IV). The most aggressive form (WHO grade IV) is called glioblastoma multiforme.

We use up-to date technology for our operations including neuronavigation, neuromonitoring and awake surgery. Besides microscopic examination of tumor tissue for diagnosis, we base our interdisciplinary treatment concept for patients with gliomas on molecular markers (MGMT, IDH, 1p19q etc.) in the tumor tissue.

Since there is still no definitive cure for most gliomas, we understand it as our responsibility as a University hospital to work for a continuous improvement of the therapy, prognosis and status of life of patients with gliomas. We therefore conduct treatment studies for patients with gliomas in our hospital and participate in multicenter studies.

Currently ongoing brain tumor studies at the UZ brussels include:

  • CATNON Intergroup Trial (EORTC 26053-22054): Phase III randomized study of radiotherapy with or without concurrent and/or adjuvant temozolomide in patients with non-1p/19q deleted anaplastic glioma
  • TAVAREC (Johnny, please add description)
  • Axitinib (Johnny, please add description)
[:fr]

Gliomas develop from the supporting cells of the brain, so-called glial cells.

Gliomas are classified by the World Health Organization in terms of their tissue structure and growth behavior into 4 grades (WHO grade I to IV). The most aggressive form (WHO grade IV) is called glioblastoma multiforme.

We use up-to date technology for our operations including neuronavigation, neuromonitoring and awake surgery. Besides microscopic examination of tumor tissue for diagnosis, we base our interdisciplinary treatment concept for patients with gliomas on molecular markers (MGMT, IDH, 1p19q etc.) in the tumor tissue.

Since there is still no definitive cure for most gliomas, we understand it as our responsibility as a University hospital to work for a continuous improvement of the therapy, prognosis and status of life of patients with gliomas. We therefore conduct treatment studies for patients with gliomas in our hospital and participate in multicenter studies.

Currently ongoing brain tumor studies at the UZ brussels include:

  • CATNON Intergroup Trial (EORTC 26053-22054): Phase III randomized study of radiotherapy with or without concurrent and/or adjuvant temozolomide in patients with non-1p/19q deleted anaplastic glioma
  • TAVAREC (Johnny, please add description)
  • Axitinib (Johnny, please add description)
[:de]

Gliomas develop from the supporting cells of the brain, so-called glial cells.

Gliomas are classified by the World Health Organization in terms of their tissue structure and growth behavior into 4 grades (WHO grade I to IV). The most aggressive form (WHO grade IV) is called glioblastoma multiforme.

We use up-to date technology for our operations including neuronavigation, neuromonitoring and awake surgery. Besides microscopic examination of tumor tissue for diagnosis, we base our interdisciplinary treatment concept for patients with gliomas on molecular markers (MGMT, IDH, 1p19q etc.) in the tumor tissue.

Since there is still no definitive cure for most gliomas, we understand it as our responsibility as a University hospital to work for a continuous improvement of the therapy, prognosis and status of life of patients with gliomas. We therefore conduct treatment studies for patients with gliomas in our hospital and participate in multicenter studies.

Currently ongoing brain tumor studies at the UZ brussels include:

  • CATNON Intergroup Trial (EORTC 26053-22054): Phase III randomized study of radiotherapy with or without concurrent and/or adjuvant temozolomide in patients with non-1p/19q deleted anaplastic glioma
  • TAVAREC (Johnny, please add description)
  • Axitinib (Johnny, please add description)
[:]